Rapamycin carbonic ester analogues, pharmaceutical compositions, preparations and uses thereof
Rapalogs of formula I, pharmaceutically acceptable salts, pharmaceutical compositions, and preparation methods and uses thereof. The rapalogs have the structure of formula I and can be used as an anti-tumor medicament. Comparing with rapamycin, the rapalogs of the present invention exhibit enhanced water solubility, and improved pharmacological and pharmacokinetic properties by introducing a hydrophilic and polar group such as a hydroxyl.
1. A compound of formula I, or a pharmaceutically acceptable salt thereof:
wherein,
R 1 is
and R 2 is H, wherein, n is an integer of 1 to 6, R 3 is
wherein R 4 , R 5 and R 6 are each independently H, C1-C6 hydroxyalkyl, C1-C6 alkyl or C2-C6 alkenyl.
2. The compound of formula I or the pharmaceutically acceptable salt thereof according to claim 1 , wherein
n is an integer of 1 to 4,
R 3 is
wherein, R 4 , R 5 and R 6 are each independently H or C1-C4 hydroxyalkyl.
3. The compound of formula I or the pharmaceutically acceptable salt thereof according to claim 2 , wherein
n is an integer of 1 to 2,
R 3 is
4. The compound of formula I or the pharmaceutically acceptable salt thereof according to claim 3 , wherein the compound is:
5. The compound of formula I or the pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound or the pharmaceutically acceptable salt thereof may be an optical isomer or a mixture thereof, when R 3 comprises a chiral site.
6. A method for preparing the compound of formula I:
wherein,
R 1 is
and R 2 is H, wherein, n is an integer of 1 to 6, R 3 is
wherein R 4 , R 5 and R 6 are each independently H, C1-C6 hydroxyalkyl, C1-C6 alkyl or C2-C6 alkenyl
wherein,
the compound is prepared according to following process:
in the presence of an proper ratio of imidazole and trimethyl chlorosilane, rapamycin reacts with trimethyl chlorosilane in a solvent selected from the group consisting of dichloromethane, dichloroethane, tetrahydrofuran, acetonitrile and DMF to produce a 31-monoprotected product rapamycin-31-OTMS; after the 42-hydroxyl of Rapamycin-31-OTMS is protected by TBS, the unstable 31-OTMS is deprotected to obtain a 42-monoprotected product rapamycin-42-OTBS, as illustrated in the following scheme:
rapamycin-31-OTMS directly reacts with the acyl chloride 3
to produce a 42-esterified product, which is then depretected the silicon protective group at 31-position to obtain the corresponding 42-monoesterified compound, the resultant compound is further hydrolyzed into a compound wherein R 3 is
7. A pharmaceutical composition having anti-tumor and anti-cancer activities or immunosuppressive activities, comprising a theraputically effective amount of one or more compound or the pharmaceutically acceptable salt thereof according to claim 1 as an active component, and one or more pharmaceutically acceptable carriers.
8. A method of treating human rhabdomyosarcoma, prostate cancer, breast cancer, renal cancer, adenocarcinoma of lung, cervix cancer, ovarian cancer, epidermoid carcinoma of the oral cavity, malignant mecanona or liver cancer comprising administering to a subject in need thereof an effective amount of the compound of formula I:
wherein,
R 1 is
and R 2 is H, wherein, n is an integer of 1 to 6, R 3 is
wherein R 4 , R 5 and R 6 are each independently H, C1-C6 hydroxyalkyl, C1-C6 alkyl or C2-C6 alkenyl, and R 7 and R 8 are each independently H or C1-C6 alkyl,
or a pharmaceutically acceptable salt thereof.